July 2 (Reuters) - Organon said on Wednesday it

will discontinue the development of its experimental drug, after

it failed to reduce pain in women suffering from endometriosis

in a mid-stage study.

The trial tested the drug, OG-6219, in women aged 18 to 49

who had moderate-to-severe endometriosis-related pain, but

results showed no significant improvement compared to a placebo.

Endometriosis is a condition where tissue similar to the

uterine lining grows outside the uterus, often causing chronic

pelvic pain and infertility.